Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to “Hold” at Wall Street Zen

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partners started coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, November 6th. Zacks Research raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Piper Sandler reduced their target price on shares of Collegium Pharmaceutical from $43.00 to $28.00 and set a “neutral” rating on the stock in a report on Friday, November 6th. Finally, Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.00.

View Our Latest Research Report on Collegium Pharmaceutical

Collegium Pharmaceutical Stock Up 0.4%

Shares of COLL opened at $25.43 on Friday. The company has a debt-to-equity ratio of 3.44, a current ratio of 1.01 and a quick ratio of 0.87. The stock has a market capitalization of $790.36 million, a price-to-earnings ratio of 3.76, a price-to-earnings-growth ratio of 0.78 and a beta of 0.75. Collegium Pharmaceutical has a 1 year low of $21.43 and a 1 year high of $50.79. The business’s 50 day simple moving average is $23.08 and its 200-day simple moving average is $32.17.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.10. Collegium Pharmaceutical had a net margin of 4.68% and a return on equity of 85.14%. The firm had revenue of $216.34 million during the quarter, compared to analyst estimates of $216.03 million. During the same period last year, the firm posted $2.25 earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 67.4% compared to the same quarter last year. As a group, equities analysts expect that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Freestone Grove Partners LP purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $1,611,000. Globeflex Capital L P bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $1,915,000. Bank of America Corp DE bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $9,882,000. Empowered Funds LLC purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth about $2,045,000. Finally, Bank of New York Mellon Corp purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth about $8,506,000.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

Further Reading

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.